Notes Conversion Offers, Stock Price Updates, Awards and Recognitions, and Tie-Ups - Analyst Notes on LabCorp, Endo Pharmaceuticals, Cognizant, YY, and Yandex

NEW YORK, April 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Laboratory Corp. of America Holdings (NYSE: LH), Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), Cognizant Technology Solutions Corporation (NASDAQ: CTSH), YY Inc. (NASDAQ: YY), and Yandex N.V. (NASDAQ: YNDX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Laboratory Corp. of America Holdings Analyst Notes 

On April 1, 2014, Laboratory Corporation of America Holdings (LabCorp) announced that holders of its Zero Coupon Convertible Subordinated Notes due 2021 (the "Notes") have the right to convert all or a portion of their Notes into cash and Common Stock of LabCorp, if any, subject to the terms of the Notes and the Indenture. The Company stated that holders willing to convert will be required to surrender their Notes during the calendar quarter through the close of business at 5:00 p.m., New York City time, on Monday, June 30, 2014. The full analyst notes on Laboratory Corp. of America Holdings are available to download free of charge at:

http://www.AnalystsReview.com/04092014/LH/report.pdf

Endo Pharmaceuticals Holdings Inc. Analyst Notes 

On April 4, 2014, stock of Endo Pharmaceuticals Holdings Inc. (Endo Pharmaceuticals) continued the southward journey for fifth consecutive session, and ended lower by 2.87% at $64.20. The shares fluctuated in the range of $63.76 - $68.46 and a total of 3.03 million shares were traded during the session. The stock is now down by 3.98% in last five trading sessions, following the announcement dated March 28, 2014 wherein the Company informed that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI") will commence offers to exchange any and all of its senior notes, which have an aggregate principal amount outstanding of $1.3 billion, for new notes issued by Endo Finance LLC and Endo Finco Inc.  In an SEC filing dated April 2, 2014, the Company informed that John Delucca, Director, sold 10,384 shares in the market on April 1, 2014 at an average price of $68.46. The full analyst notes on Endo Pharmaceuticals Holdings Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/ENDP/report.pdf

Cognizant Technology Solutions Corporation Analyst Notes 

On April 2, 2014, Cognizant Technology Solutions Corporation (Cognizant) announced that it has debuted amongst the Top 50 on this year's InformationWeek Elite 100 list of the top business technology innovators in the U.S. The Company informed that the theme of the 2014 InformationWeek Elite 100 was digital business: a movement rooted in data analytics, mobile computing, social networking and other customer-focused technologies that are turning companies and industries on their ear. The full analyst notes on Cognizant Technology Solutions Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04092014/CTSH/report.pdf

YY Inc. Analyst Notes 

On April 4, 2013, the stock (ADR) of YY Inc. (YY) declined for the third consecutive session and ended lower by 6.67% at $68.65 after seeing high intra-day volatility. The Company's stock opened at $75.61 and oscillated in the range $67.23 - $75.61 during the trading session. During the session, a total of 3.00 million ADRs were traded, which was higher than its 30-day average. On March 31, 2014, the Company announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2013 with the Securities and Exchange Commission on March 17, 2014. The full analyst notes on YY Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/YY/report.pdf

Yandex N.V. Analyst Notes  

On April 2, 2014, Yandex N.V. (Yandex) announced that it has teamed up with the Higher School of Economics to open a Faculty of Computer Science, aimed at preparing specialists in two areas - Applied Mathematics and Informatics, and Software Engineering. The Company informed that Ivan Arzhantsev, who has been heading Yandex's academic programs, will be appointed as the Dean of the Faculty. Commenting the development, Yandex CEO, Arkady Volozh said, "Together with the HSE, we want to create a faculty where people can receive a full education in this field. We are sure they will be in demand in academia as well as in IT companies." Yandex further informed that the faculty includes the HSE's existing Department of Software Engineering and Department of Applied Mathematics and Informatics, and will be supplemented by the addition of a new department - Big Data and Information Retrieval. The full analyst notes on Yandex N.V. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/YNDX/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review